Philippe M Loiseau

List of Publications by Year
in descending order

191	5,393	87888 38	128289 60
papers	citations	h-index	g-index

205	205	205	6773
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Miltefosine Induces Apoptosis-Like Death in Leishmania donovani Promastigotes. Antimicrobial Agents and Chemotherapy, 2004, 48, 852-859.	3.2	297
2	Mechanism of Amphotericin B Resistance in Leishmania donovani Promastigotes. Antimicrobial Agents and Chemotherapy, 1998, 42, 352-357.	3.2	181
3	Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 815-820.	2.2	172
4	Antiparasitic activities of medicinal plants used in Ivory Coast. Journal of Ethnopharmacology, 2004, 90, 91-97.	4.1	154
5	Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 809-813.	2.2	124
6	Alteration of Fatty Acid and Sterol Metabolism in Miltefosine-Resistant Leishmania donovani Promastigotes and Consequences for Drug-Membrane Interactions. Antimicrobial Agents and Chemotherapy, 2005, 49, 2677-2686.	3.2	119
7	Efficacy and Pharmacokinetics of Intravenous Nanocapsule Formulations of Halofantrine in Plasmodium berghei -Infected Mice. Antimicrobial Agents and Chemotherapy, 2004, 48, 1222-1228.	3.2	90
8	In Vitro Antileishmanial Activity of Amphotericin B Loaded in Poly(Îµ-Caprolactone) Nanospheres. Journal of Drug Targeting, 2002, 10, 593-599.	4.4	87
9	Efficacy of Orally Administered 2-Substituted Quinolines in Experimental Murine Cutaneous and Visceral Leishmaniases. Antimicrobial Agents and Chemotherapy, 2005, 49, 4950-4956.	3.2	86
10	LeishmaniaResistance to Miltefosine Associated with Genetic Marker. Emerging Infectious Diseases, 2012, 18, 704-706.	4.3	86
11	Comparison between charged aerosol detection and light scattering detection for the analysis of Leishmania membrane phospholipids. Journal of Chromatography A, 2008, 1209, 88-94.	3.7	85
12	Ionic liquid mediated and promoted eco-friendly preparation of thiazolidinone and pyrimidine nucleosideâ€“thiazolidinone hybrids and their antiparasitic activities. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6280-6283.	2.2	84
13	Hexadecylphosphocholine interaction with lipid monolayers. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1661, 212-218.	2.6	81
14	Strategies for Prevention and Treatment of Trichomonas vaginalis Infections. Clinical Microbiology Reviews, 2017, 30, 811-825.	13.6	81
15	Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite, 2011, 18, 115-119.	2.0	79
16	Amphotericin B-Gum Arabic Conjugates: Synthesis, Toxicity, Bioavailability, and Activities Against Leishmania and Fungi. Pharmaceutical Research, 2007, 24, 971-980.	3.5	75
17	Clotrimazole-loaded nanostructured lipid carrier hydrogels: Thermal analysis and in vitro studies. International Journal of Pharmaceutics, 2013, 454, 695-702.	5.2	70
18	Medicinal plants and finished marketed herbal products used in the treatment of malaria in the Ashanti region, Ghana. Journal of Ethnopharmacology, 2015, 172, 333-346.	4.1	70

#	Article	IF	Citations
19	Cloning of S -Adenosyl- l -Methionine:C-24-Î”-Sterol-Methyltransferase (ERG6) from Leishmania donovani and Characterization of mRNAs in Wild-Type and Amphotericin B-Resistant Promastigotes. Antimicrobial Agents and Chemotherapy, 2004, 48, 2409-2414.	3.2	65
20	Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrobial Agents and Chemotherapy, 2003, 47, 3774-3779.	3.2	61
21	Bioactive properties of plant species ingested by chimpanzees (Pan troglodytes schweinfurthii) in the Kibale National Park, Uganda. American Journal of Primatology, 2006, 68, 51-71.	1.7	58
22	Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis. Analytical and Bioanalytical Chemistry, 2012, 402, 1169-1182.	3.7	55
23	Cellular Transport and Lipid Interactions of Miltefosine. Current Drug Metabolism, 2009, 10, 247-255.	1.2	53
24	VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis. Journal of Infectious Diseases, 2015, 212, 1439-1448.	4.0	51
25	Antiparasitic Activity ofAnnona muricataandAnnona cherimoliaSeeds. Planta Medica, 1991, 57, 434-436.	1.3	50
26	Drosophila PAT1 is required for Kinesin-1 to transport cargo and to maximize its motility. Development (Cambridge), 2010, 137, 2763-2772.	2.5	50
27	Strategies for the design of orally bioavailable antileishmanial treatments. International Journal of Pharmaceutics, 2013, 454, 539-552.	5.2	50
28	Cytotoxic and Antiparasitic Activity fromAnnona senegalensisSeeds*. Planta Medica, 1994, 60, 538-540.	1.3	47
29	Revisiting Previously Investigated Plants: A Molecular Networking-Based Study of Geissospermum laeve. Journal of Natural Products, 2017, 80, 1007-1014.	3.0	45
30	In situ forming pluronicÂ® F127/chitosan hydrogel limits metronidazole transmucosal absorption. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 143-147.	4.3	45
31	Comparison of electrospray ionization, atmospheric pressure chemical ionization and atmospheric pressure photoionization for a lipidomic analysis of Leishmania donovani. Journal of Chromatography A, 2012, 1242, 75-83.	3.7	44
32	Leishmania hijacking of the macrophage intracellular compartments. FEBS Journal, 2016, 283, 598-607.	4.7	43
33	Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. Expert Opinion on Drug Delivery, 2019, 16, 1063-1079.	5.0	43
34	Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. Journal of Antimicrobial Chemotherapy, 2009, 64, 993-1001.	3.0	42
35	In Vitro Activities of New 2-Substituted Quinolines against Leishmania donovani. Antimicrobial Agents and Chemotherapy, 2011, 55, 1777-1780.	3.2	42
36	Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research, 2015, 4, 34.	1.6	41

#	Article	IF	Citations
37	Mechanisms of Drug Action and Drug Resistance in Leishmania as Basis for Therapeutic Target Identification and Design of Antileishmanial Modulators. Current Topics in Medicinal Chemistry, 2006, 6, 539-550.	2.1	39
38	Drug-Free Chitosan Coated Poly(isobutylcyanoacrylate) Nanoparticles Are Active Against Trichomonas vaginalis and Non-Toxic Towards Pig Vaginal Mucosa. Pharmaceutical Research, 2015, 32, 1229-1236.	3.5	39
39	Selective elution and purification of living Trichomonas vaginalis using gravitational field-flow fractionation. Biomedical Applications, 1995, 664, 444-448.	1.7	38
40	Contribution of Dithiol Ligands to In Vitro and In Vivo Trypanocidal Activities of Dithiaarsanes and Investigation of Ligand Exchange in an Aqueous Solution. Antimicrobial Agents and Chemotherapy, 2000, 44, 2954-2961.	3.2	38
41	Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomedicine and Pharmacotherapy, 2008, 62, 684-689.	5.6	38
42	The auto-inhibitory domain and ATP-independent microtubule-binding region of Kinesin heavy chain are major functional domains for transport in theDrosophilagermline. Development (Cambridge), 2014, 141, 176-186.	2.5	37
43	Synthesis and in vitro antileishmanial activity of 5-substituted-2â€²-deoxyuridine derivatives. Bioorganic Chemistry, 2005, 33, 439-447.	4.1	36
44	Antileishmanial andÂtrypanocidal activities ofÂnew miltefosine liposomal formulations. Biomedicine and Pharmacotherapy, 2005, 59, 545-550.	5.6	35
45	Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 246-252.	2.6	35
46	In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice. Journal of Pharmacy and Pharmacology, 2010, 55, 647-652.	2.4	35
47	In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188. Antimicrobial Agents and Chemotherapy, 2000, 44, 2190-2192.	3.2	34
48	In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Biomedicine and Pharmacotherapy, 2007, 61, 186-188.	5.6	33
49	A novel 1-indanone isolated from Uvaria afzelii roots. Natural Product Research, 2009, 23, 909-915.	1.8	32
50	Klaivanolide, an antiprotozoal lactone from Uvaria klaineana. Phytochemistry, 2002, 59, 885-888.	2.9	31
51	Antiplasmodial activity of selected medicinal plants used to treat malaria in Ghana. Parasitology Research, 2016, 115, 3185-3195.	1.6	31
52	Interaction between Miltefosine and Amphotericin B: Consequences for Their Activities towards Intestinal Epithelial Cells and Leishmania donovani Promastigotes In Vitro. Antimicrobial Agents and Chemotherapy, 2006, 50, 3793-3800.	3.2	30
53	Synthesis and anti-leishmanial activity of 1-aryl-Î²-carboline derivatives against Leishmania donovani. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3905-3907.	2.2	30
54	Antiprotozoal activity of medicinal plants used by Iquitos-Nauta road communities in Loreto (Peru). Journal of Ethnopharmacology, 2018, 210, 372-385.	4.1	30

#	Article	IF	Citations
55	Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II. International Journal of Pharmaceutics, 2011, 416, 402-409.	5.2	29
56	Synthesis and antikinetoplastid activities of 3-substituted quinolinones derivatives. European Journal of Medicinal Chemistry, 2012, 52, 44-50.	5.5	29
57	Investigation of the complexation of albendazole with cyclodextrins for the design of new antiparasitic formulations. Carbohydrate Research, 2014, 398, 50-55.	2.3	29
58	A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. International Journal of Pharmaceutics, 2020, 586, 119390.	5.2	29
59	Acaricidal Activity of Tonka Bean Extracts. Synthesis and Structureâ^'Activity Relationships of Bioactive Derivatives. Journal of Natural Products, 2003, 66, 690-692.	3.0	28
60	Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin Bâ€“miltefosine-loaded nanocochleates. Colloids and Surfaces B: Biointerfaces, 2013, 106, 224-233.	5.0	28
61	Gelation and micellization behaviors of pluronicÂ® F127 hydrogel containing poly(isobutylcyanoacrylate) nanoparticles specifically designed for mucosal application. Colloids and Surfaces B: Biointerfaces, 2015, 135, 669-676.	5.0	28
62	Characterisation of atovaquone resistance in Leishmania infantum promastigotes. International Journal for Parasitology, 2002, 32, 1043-1051.	3.1	27
63	The Ugi reaction in the generation of new nucleosides as potential antiviral and antileishmanial agents. Bioorganic Chemistry, 2007, 35, 121-136.	4.1	27
64	In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion. Experimental Parasitology, 2018, 192, 85-92.	1.2	27
65	Synthesis and in vitro Trichomonacidal activities of some new dialkylperoxides and 1,2,4-trioxanes. European Journal of Medicinal Chemistry, 2001, 36, 837-842.	5.5	25
66	Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomedicine and Pharmacotherapy, 2008, 62, 164-167.	5.6	25
67	Synthesis of novel guttiferone A derivatives: In-vitro evaluation toward Plasmodium falciparum, Trypanosoma brucei and Leishmania donovani. European Journal of Medicinal Chemistry, 2013, 65, 284-294.	5.5	25
68	In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl Î²-cyclodextrin formulation and pharmacokinetics via intravenous route. Biomedicine and Pharmacotherapy, 2015, 76, 127-133.	5.6	25
69	Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales. Chemico-Biological Interactions, 2017, 267, 96-103.	4.0	25
70	Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against Leishmania donovani. Molecules, 2020, 25, 465.	3.8	25
71	In vitro antileishmanial activity of acetogenins from Annonaceae. Biomedicine and Pharmacotherapy, 2004, 58, 388-392.	5.6	24
72	Synthesis ofÂoxysterols andÂnitrogenous sterols with antileishmanial andÂtrypanocidal activities. European Journal of Medicinal Chemistry, 2006, 41, 1109-1116.	5.5	24

#	Article	IF	Citations
73	In vitro antileishmanial and antitrypanosomal activities of five medicinal plants from Burkina Faso. Parasitology Research, 2012, 110, 1779-1783.	1.6	24
74	Supramolecular Chitosan Micro-Platelets Synergistically Enhance Anti-Candida albicans Activity of Amphotericin B Using an Immunocompetent Murine Model. Pharmaceutical Research, 2017, 34, 1067-1082.	3.5	24
75	Biochemical analysis of leishmanial and human GDP-Mannose Pyrophosphorylases and selection of inhibitors as new leads. Scientific Reports, 2017, 7, 751.	3.3	24
76	In vivoantileishmanial action of Ir-(COD)-pentamidine tetraphenylborate onLeishmania donovaniandLeishmania majormouse models. Parasite, 2000, 7, 103-108.	2.0	23
77	Design and Antileishmanial Activity of Amphotericin B-Loaded Stable Ionic Amphiphile Biovector Formulations. Antimicrobial Agents and Chemotherapy, 2002, 46, 1597-1601.	3.2	23
78	Antifungal canthin-6-one series accumulate in lipid droplets and affect fatty acid metabolism in Saccharomyces cerevisiae. Biomedicine and Pharmacotherapy, 2008, 62, 99-103.	5.6	23
79	Drugs used for the treatment of cerebral and disseminated infections caused by freeâ€living amoebae. Clinical and Translational Science, 2021, 14, 791-805.	3.1	23
80	Antileishmanial 2-substituted quinolines: In vitro behaviour towards biological components. Biomedicine and Pharmacotherapy, 2007, 61, 441-450.	5.6	22
81	Mechanism of interaction of sitamaquine with Leishmania donovani. Journal of Antimicrobial Chemotherapy, 2010, 65, 2548-2555.	3.0	21
82	Antimalarial Activity of Axidjiferosides, New Î²-Galactosylceramides from the African Sponge Axinyssa djiferi. Marine Drugs, 2013, 11, 1304-1315.	4.6	21
83	Anti-fungal and anti-leishmanial activities of pectin-amphotericin B conjugates. Journal of Drug Delivery Science and Technology, 2017, 39, 1-7.	3.0	21
84	Enrichment of free-living amoebae in biofilms developed at upper water levels in drinking water storage towers: An inter- and intra-seasonal study. Science of the Total Environment, 2018, 633, 157-166.	8.0	21
85	Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani. Acta Tropica, 1998, 70, 239-245.	2.0	20
86	Squamocin and Benzyl Benzoate, Acaricidal Components ofUvaria pauci-ovulataBark Extracts. Planta Medica, 2000, 66, 173-175.	1.3	20
87	Structurally diverse 5-substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5047-5051.	2.2	20
88	In vitro antileishmanial activity of fluoro-artemisinin derivatives against Leishmania donovani. Biomedicine and Pharmacotherapy, 2008, 62, 462-465.	5.6	20
89	Solvent-Free Synthesis of Pyrimidine Nucleoside-Aminophosphonate Hybrids and Their Biological Activity Evaluation. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 616-627.	1.1	20
90	â€œSqualenoylcurcuminâ€•Nanoassemblies as Waterâ€Dispersible Drug Candidates with Antileishmanial Activity. ChemMedChem, 2015, 10, 411-418.	3.2	20

#	Article	IF	Citations
91	Antiplasmodial Securinega alkaloids from Phyllanthus fraternus: Discovery of natural (+)-allonorsecurinine. Tetrahedron Letters, 2017, 58, 3754-3756.	1.4	19
92	InÂvitro evaluation of antimicrobial agents on Acanthamoeba sp. and evidence of a natural resilience to amphotericin B. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 328-336.	3.4	19
93	The chitinase system from Trichomonas vaginalis as a potential target for antimicrobial therapy of urogenital trichomoniasis. Biomedicine and Pharmacotherapy, 2002, 56, 503-510.	5.6	18
94	Membrane lipidomics for the discovery of new antiparasitic drug targets. Trends in Parasitology, 2011, 27, 496-504.	3.3	18
95	Synthesis and antiprotozoal activity of original porphyrin precursors and derivatives. European Journal of Medicinal Chemistry, 2013, 67, 158-165.	5.5	18
96	New heterocyclic compounds: Synthesis and antitrypanosomal properties. Bioorganic and Medicinal Chemistry, 2015, 23, 5168-5174.	3.0	18
97	Surface-dependent endocytosis of poly(isobutylcyanoacrylate) nanoparticles by Trichomonas vaginalis. International Journal of Pharmaceutics, 2018, 548, 276-287.	5.2	18
98	Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections. Molecules, 2020, 25, 5075.	3.8	18
99	Antiplasmodial Activity of Acetogenins and Inhibitory Effect onPlasmodium falciparumAdenylate Translocase. Journal of Chemotherapy, 2004, 16, 350-356.	1.5	17
100	Screening of New Caledonian and Vanuatu medicinal plants for antiprotozoal activity. Journal of Ethnopharmacology, 2005, 96, 569-575.	4.1	17
101	In-vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCl: a diglyceride prodrug. Journal of Pharmacy and Pharmacology, 2011, 41, 191-193.	2.4	17
102	Diarylheptanoid Glucosides from Pyrostria major and Their Antiprotozoal Activities. European Journal of Organic Chemistry, 2012, 2012, 1039-1046.	2.4	17
103	Development of antileishmanial lipid nanocomplexes. Biochimie, 2014, 107, 143-153.	2.6	17
104	Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors. European Journal of Medicinal Chemistry, 2016, 109, 173-186.	5.5	17
105	Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Tropical Medicine and International Health, 1996, 1, 379-384.	2.3	16
106	Cell line-dependent cytotoxicity of poly(isobutylcyanoacrylate) nanoparticles coated with chitosan and thiolated chitosan: Insights from cultured human epithelial HeLa, Caco2/TC7 and HT-29/MTX cells. International Journal of Pharmaceutics, 2015, 491, 17-20.	5.2	16
107	In Silico Mining for Antimalarial Structure-Activity Knowledge and Discovery of Novel Antimalarial Curcuminoids. Molecules, 2016, 21, 853.	3.8	16
108	Synthetic Polysaccharides as Drug Carriers: Synthesis of Polyglucose-Amphotericin B Conjugates and In Vitro Evaluation of Their Anti-Fungal and Anti-Leishmanial Activities. Journal of Nanoscience and Nanotechnology, 2018, 18, 2405-2414.	0.9	16

#	Article	IF	Citations
109	Topically Applied Chitosan-Coated Poly(isobutylcyanoacrylate) Nanoparticles Are Active Against Cutaneous Leishmaniasis by Accelerating Lesion Healing and Reducing the Parasitic Load. ACS Applied Bio Materials, 2019, 2, 2573-2586.	4.6	16
110	In vitro antileishmanial properties of new flavonoids against Leishmania donovani. Biomedicine and Preventive Nutrition, 2011, 1, 168-171.	0.9	15
111	Antiprotozoal activity of ferroquine. Parasitology Research, 2013, 112, 665-669.	1.6	15
112	Polyamine-based analogs and conjugates as antikinetoplastid agents. European Journal of Medicinal Chemistry, 2017, 139, 982-1015.	5.5	15
113	Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets. Molecules, 2019, 24, 1282.	3.8	15
114	In vitro antileishmanial potentialities of essential oils from Citrus limon and Pistacia lentiscus harvested in Tunisia. Parasitology Research, 2021, 120, 1455-1469.	1.6	15
115	Synthesis and protozoocidal activities of quinones. European Journal of Medicinal Chemistry, 1996, 31, 507-511.	5.5	14
116	Bioactive phloroglucinols from Mallotus oppositifolius. FÃ¬toterapÃ¬Ã¢, 2015, 107, 100-104.	2.2	14
117	Simple and efficient synthesis of $$5'$$ 5 â€² -aryl- $$5'$$ 5 â€² -deoxyguanosine analogs by azide-alkyne click reaction and their antileishmanial activities. Molecular Diversity, 2016, 20, 507-519.	3.9	14
118	InÂvitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L.Âmajor casein kinase 1 inhibition. European Journal of Medicinal Chemistry, 2021, 210, 112956.	5.5	14
119	Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. Pharmaceutics, 2022, 14, 989.	4.5	14
120	Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model. Parasite, 2011, 18, 333-336.	2.0	13
121	The unexpected increase of clotrimazole apparent solubility using randomly methylated Î²â€cyclodextrin. Journal of Molecular Recognition, 2015, 28, 96-102.	2.1	13
122	Synthesis of 5-isoxazol-3-yl-pyrimidine nucleosides as potential antileishmanial agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2617-2620.	2.2	13
123	Cyclodextrin-mediated self-associating chitosan micro-platelets act as a drug booster against Candida glabrata mucosal infection in immunocompetent mice. International Journal of Pharmaceutics, 2017, 519, 381-389.	5.2	13
124	ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments. Scientific Reports, 2017, 7, 15567.	3.3	13
125	Comparative study of structural models of Leishmania donovani and human GDP-mannose pyrophosphorylases. European Journal of Medicinal Chemistry, 2016, 107, 109-118.	5.5	12
126	Purification and characterization of lactate dehydrogenase isoenzymes 1 and 2 from Molinema dessetae (Nematoda: Filarioidea). Parasitology Research, 1996, 82, 672-680.	1.6	11

#	Article	IF	Citations
127	Lymphotropic antifilarial agents derived from closantel and chlorambucil. International Journal for Parasitology, 1997, 27, 443-447.	3.1	11
128	Isolation of bloodstream trypanosomes by sedimentation field-flow fractionation. Journal of Separation Science, 1997, 9, 469-477.	1.0	11
129	Chitinolytic activities inTrichomonas vaginalis. Parasite, 1998, 5, 75-78.	2.0	11
130	Trypanocidal activity of arsonoliposomes: Effect of vesicle lipid composition. Biomedicine and Pharmacotherapy, 2007, 61, 499-504.	5.6	11
131	In silicoanalysis of a therapeutic target inLeishmania infantum: the guanosine-diphospho-D-mannose pyrophosphorylase. Parasite, 2012, 19, 63-70.	2.0	11
132	Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis. PLoS Neglected Tropical Diseases, 2021, 15, e0009627.	3.0	11
133	Polysorbate Surfactants as Drug Carriers: Tween 20-Amphotericin B Conjugates as Anti-Fungal and Anti-Leishmanial Agents. Current Drug Delivery, 2018, 15, 1028-1037.	1.6	11
134	Phase solubility studies and anti-Trichomonas vaginalis activity evaluations of metronidazole and methylated Î²-cyclodextrin complexes: Comparison of CRYSMEB and RAMEB. Experimental Parasitology, 2018, 189, 72-75.	1.2	10
135	In vitro antifilarial evaluation of phenoxycyclohexane derivatives. Annals of Tropical Medicine and Parasitology, 1993, 87, 469-476.	1.6	9
136	Sitamaquine-resistance in Leishmania donovani affects drug accumulation and lipid metabolism. Biomedicine and Pharmacotherapy, 2014, 68, 893-897.	5.6	9
137	Design, synthesis and in vitro antikinetoplastid evaluation of N-acylated putrescine, spermidine and spermine derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 207-209.	2.2	9
138	Combination of amphotericin B and chitosan platelets for the treatment of experimental cutaneous leishmaniasis: Histological and immunohistochemical examinations. Journal of Drug Delivery Science and Technology, 2019, 50, 34-41.	3.0	9
139	The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates. Molecules, 2022, 27, 2313.	3.8	9
140	Synthesis and nematocidal activities of new analogs of pyrantel. European Journal of Medicinal Chemistry, 1995, 30, 509-513.	5.5	8
141	N-acetyl-Î²-d-hexosaminidase from Trichomonas vaginalis: substrate specificity and activity of inhibitors. Biomedicine and Pharmacotherapy, 2005, 59, 245-248.	5.6	8
142	Synthesis and in vitro antikinetoplastid activity of polyamineâ€“hydroxybenzotriazole conjugates. Bioorganic and Medicinal Chemistry, 2017, 25, 84-90.	3.0	8
143	Synthesis and antikinetoplastid evaluation of bis(benzyl)spermidine derivatives. European Journal of Medicinal Chemistry, 2018, 150, 655-666.	5.5	8
144	Recent strategies for the chemotherapy of visceral leishmaniasis. Current Opinion in Infectious Diseases, 1999, 12, 559-564.	3.1	8

#	Article	IF	Citations
145	Synthesis and biological evaluation of ureido and thioureido derivatives of 2-amino-2-deoxy-d-glucose and related aminoalcohols as N-acetyl-Î²-d-hexosaminidase inhibitors. Carbohydrate Research, 1998, 314, 47-63.	2.3	7
146	Introduction of methionine mimics on 3-arylthiophene: influence on protein farnesyltransferase inhibition and on antiparasitic activity. MedChemComm, 2013, 4, 1034.	3.4	7
147	Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds. MedChemComm, 2019, 10, 120-127.	3.4	7
148	GDP-Mannose Pyrophosphorylase: A Biologically Validated Target for Drug Development Against Leishmaniasis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 186.	3.9	7
149	An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy, 2021, 76, 2640-2650.	3.0	7
150	Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research, 0, 4, 34.	1.6	7
151	Adsorption of Antisense Oligonucleotides Targeting Malarial Topoisomerase II on Cationic Nanoemulsions Optimized by a Full Factorial Design. Current Topics in Medicinal Chemistry, 2014, 14, 1161-1171.	2.1	7
152	Inhibition of in vitro Ebola infection by anti-parasitic quinoline derivatives. F1000Research, 2020, 9, 268.	1.6	7
153	Antileishmanial activity of Opuntia ficus-indica fractions. Biomedicine and Preventive Nutrition, 2014, 4, 101-104.	0.9	6
154	Isoenzymatic diagnosis of filariae: a method for separation of lactate dehydrogenase isoenzymes from Molinema dessetae (Nematoda: Filarioidea). Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1994, 109, 451-457.	0.2	5
155	Synthesis, antifungal and nematocidal activities of thioureines with an aminoester sequence. European Journal of Medicinal Chemistry, 1995, 30, 801-807.	5.5	5
156	Action of DNA-gyrase inhibiting derivatives of 4-oxo-1, 4-dihydro-3-pyridinecarboxylic acid against Trypanosoma brucei. International Journal for Parasitology, 1995, 25, 403-405.	3.1	5
157	Studies on lipidomimetic derivatives of Î±-difluoromethylornithine (DFMO) to enhance the bioavailability in aTrypanosoma b. bruceimurine trypanosomiasis model. Parasite, 1998, 5, 239-246.	2.0	5
158	SYNTHESIS AND PROTOZOOCIDAL ACTIVITY OF NEW 1,4-NAPHTHOQUINONES. Heterocyclic Communications, 1999, 5, .	1.2	5
159	Perspectives for parasitology and parasitology networks in Europe. Trends in Parasitology, 2009, 25, 293-295.	3.3	5
160	Spermine-NBD as fluorescent probe for studies of the polyamine transport system in Leishmania donovani. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1710-1713.	2.2	5
161	Trichomonas vaginalis Motility Is Blocked by Drug-Free Thermosensitive Hydrogel. ACS Infectious Diseases, 2020, 6, 114-123.	3.8	5
162	Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis. Molecules, 2020, 25, 4123.	3.8	5

#	Article	IF	Citations
163	Alkyl-Resorcinol Derivatives as Inhibitors of GDP-Mannose Pyrophosphorylase with Antileishmanial Activities. Molecules, 2021, 26, 1551.	3.8	5
164	Anti-protozoal and anti-fungal evaluation of 3,5-disubstituted 1,2-dioxolanes. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128196.	2.2	5
165	SynthÃ¨se, activitÃ© antiparasitaire et antifongique de thiourÃ©ines Ã motif aminoacide. European Journal of Medicinal Chemistry, 1991, 26, 723-727.	5.5	4
166	Synthesis and nematocidal activities of arylvinyltetrahydropyrimidines. European Journal of Medicinal Chemistry, 1993, 28, 979-982.	5.5	4
167	Antileishmanial activity of rac-1-dodecy1-2-octanamido-2-deoxy-glycerophosphocholine, a new dialkylglycerophosphocholine, in vitro. Annals of Tropical Medicine and Parasitology, 1996, 90, 559-561.	1.6	4
168	A New Photometric Assay with Bromocresol Purple for Testing in vitro Antitrichomonal Activity in Aerobic Environment. Arzneimittelforschung, 1999, 49, 51-55.	0.4	4
169	Antifungal and Anthelmintic Activities ofCleistopholis patens(Annonaceae). Planta Medica, 2009, 75, 1143-1145.	1.3	4
170	New Anti-Malarial Drugs: Who Cares?. Current Topics in Medicinal Chemistry, 2014, 14, 1637-1642.	2.1	4
171	Synthesis and Antileishmanial Activity of Pyrimidine Nucleoside- Chalcone Hybrids. Chinese Journal of Organic Chemistry, 2015, 35, 1335.	1.3	4
172	Effect of chronic trypanosomiasis on the bioavailability of Î±-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay. Parasitology Research, 1997, 83, 386-389.	1.6	3
173	Purification of N-Acetyl-Î²-d-hexosaminidase from Trichomonas vaginalis. Experimental Parasitology, 2001, 97, 169-172.	1.2	3
174	Targeting sterol metabolism for the development of antileishmanials. Trends in Parasitology, 2015, 31, 5-7.	3.3	3
175	Freeze-Dried Microemulsion Containing Amphotericin B for Leishmaniasis Treatment: An Overview. Journal of Colloid Science and Biotechnology, 2016, 5, 55-68.	0.2	3
176	Research for new filaricides by using phosphoenolpyruvate-carboxylase from Molinema dessetae (Nematoda: Filarioidea) as biochemical target. International Journal for Parasitology, 1993, 23, 697-698.	3.1	2
177	The incorporation of N,Nâ€²- bis(2,3-dihydroxybenzoyl)-1,6 diazahexane or octane as the ligands of spiroarsoranes: their effect on trypanocidal activity. Acta Tropica, 1995, 59, 237-241.	2.0	2
178	The effect of spiroarsoranes on Trypanosoma brucei brucei and T. b. rhodesiense. Parasitology Research, 1996, 82, 477-480.	1.6	2
179	Tissue distribution and metabolism in rat of an ethynesulphonamide with filaricidal activity. Xenobiotica, 1997, 27, 73-85.	1.1	2
180	Synthesis and trichomonacidal activity of perketals and hydroperoxides. Il Farmaco, 2002, 57, 457-462.	0.9	2

#	Article	IF	Citations
181	New Water-Soluble Polymeric Prodrugs of 2-n-propylquinoline: Synthesis and Evaluation of In Vitro and In Vivo Activities Against Leishmania donovani. Regenerative Engineering and Translational Medicine, 2018, 4, 11-20.	2.9	2
182	Minor Impact of A258D Mutation on Biochemical and Enzymatic Properties of Leishmania infantum GDP-Mannose Pyrophosphorylase. Microorganisms, 2022, 10, 231.	3.6	2
183	Targeting chalcone binding sites in living Leishmania using a reversible fluorogenic benzochalcone probe. Biomedicine and Pharmacotherapy, 2022, 149, 112784.	5.6	2
184	Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model. International Journal of Pharmaceutics, 2022, 624, 121985.	5.2	2
185	Structure-activity relationships for new organometallic complexes active against bloodstream forms of Trypanosoma brucei brucei. Parasitology Research, 2001, 87, 566-569.	1.6	1
186	Apoprunellelactone (APL), an antiprotozoal lactone from the stem barks ofIsolona cooperiHutch. & Dalziel (Annonaceae). Natural Product Research, 2020, 35, 1-8.	1.8	1
187	Kinetic parameters of N-acetylglucosaminidase in adult femaleNippostrongylus brasiliensisby a quantitative colorimetric micromethod. Parasite, 1996, 3, 115-118.	2.0	0
188	Drug Targets, Drug Effectors, and Drug Targeting and Delivery. , 2013, , 321-350.		0
189	Drosophila PAT1 is required for Kinesin-1 to transport cargo and to maximize its motility. Journal of Cell Science, 2010, 123, e1-e1.	2.0	0
190	The auto-inhibitory domain and ATP-independent microtubulebinding region of Kinesin heavy chain are major functional domains for transport in the Drosophila germline. Journal of Cell Science, 2014, 127, e1-e1.	2.0	0
191	Biodereplication approach for antimalarial drugs in complex extracts mixtures: active compounds from the insect Pyrrhocoris apterus. Planta Medica, 2016, 81, S1-S381.	1.3	0